RedHill Biopharma (RDHL) Tops Q2 EPS by 6c, Revenue Misses Consensus

RedHill Biopharma (NASDAQ: RDHL) reported Q2 EPS of ($0.06), $0.06 better than the analyst estimate of ($0.12). Revenue for the quarter came in at $21.5 million versus the consensus estimate of $25.02 million.

For earnings history and earnings-related data on RedHill Biopharma (RDHL) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Trinity Capital posts $709M in new commitments for Q2 2026
• Mizuho upgrades five below on valuation, sees over 20% upside